Our review summarizes the current clinical evidence on anti-IL23p19 therapies and provides practical guidance on their use in IBD clinical management, including dosing strategies, choice of dose in CD and UC, and clinical positioning across patients. This evidence concerns the gene IL23A and inflammatory bowel disease.